ProQR Therapeutics (NASDAQ:PRQR) Receives $8.83 Average Price Target from Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR) have earned a consensus recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $8.83.

PRQR has been the topic of a number of recent research reports. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com lowered ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Oppenheimer started coverage on ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target for the company. JMP Securities reiterated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th.

Institutional Trading of ProQR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in PRQR. Jane Street Group LLC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth $30,000. Invesco Ltd. acquired a new stake in ProQR Therapeutics in the 4th quarter valued at $32,000. Alpine Global Management LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at $39,000. Two Sigma Securities LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at $40,000. Finally, ADAR1 Capital Management LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at $54,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Stock Performance

PRQR stock opened at $2.13 on Tuesday. ProQR Therapeutics has a 1 year low of $1.61 and a 1 year high of $4.62. The stock’s 50 day moving average price is $2.40 and its 200 day moving average price is $2.64. The firm has a market cap of $173.98 million, a P/E ratio of -6.66 and a beta of 0.25.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).